Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy

American Journal of Pathology

Volumn 162, Issue 1, 2003, Pages 183-193

  Gee, Michael S ^a   Procopio, William N ^a   Makonnen, Sosina ^a   Feldman, Michael D ^a   Yeilding, Newman M ^a,b   Lee, William M F ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BRB II/III   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 12;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; MATURATION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERICYTE; PRIORITY JOURNAL; TUMOR; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME;

EID: 0037223555     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63809-6     Document Type: Article

References (30)

1. Giavazzi R, Taraboletti G: Angiogenesis and angiogenesis inhibitors in cancer. Forum (Genova) 1999, 9:261-272
2. Folkman J: Angiogenesis research: From laboratory to clinic. Forum (Genova) 1999, 9:59-62
3. Gee MS, Koch CJ, Evans SM, Jenkins WT, Pletcher CH, Moore JS, Koblish HK, Lee J, Lord EM, Trinchieri G, Lee WMF: Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res 1999, 59:4882-4889
4. Folkman J: Anti-angiogenesis: New concept for therapy of solid tumors. Ann Surg 1972, 175:409-416
5. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991, 13:31-36
6. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390:404-407
7. Shaheen RM, Tseng WW, Davis DW, Liu W, Reinmuth N, Vellagas R, Wieczorek AA, Ogura Y, McConkey DJ, Drazan KE, Bucana CD, McMahon, G, Ellis LM: Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 2001, 61:1464-1468
8. Gee MS, Saunders HM, Lee JC, Sanzo JF, Jenkins WT, Evans SM, Trinchieri G, Sehgal CM, Feldman MD, Lee WM: Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res 2001, 61:2974-2982
9. Darland DC, D'Amore PA: Blood vessel maturation: Vascular development comes of age. J Clin Invest 1999, 103:157-158
10. Warren BA, Shubik P: The growth of the blood supply to melanoma transplants in the hamster cheek pouch. Lab Invest 1966, 15:464-478
11. Ausprunk DH, Knighton DR, Folkman J: Differentiation of vascular endothelium in the chick chorioallantois: A structural and autoradiographic study. Dev Biol 1974, 38:237-248
12. Crocker DJ, Murad TM, Geer JC: Role of the pericyte in wound healing. An ultrastructural study. Exp Mol Pathol 1970, 13:51-65
13. Benjamin LE, Hemo I, Keshet E: A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998, 125:1591-1598
14. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995, 1:1024-1028
15. Lindahl P, Johansson BR, Leveen P, Betsholtz C: Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277:242-245
16. Kripke ML: Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J Natl Cancer Inst 1979, 63: 541-548
17. Fidler IJ: Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 1975, 35:218-224
18. Murphy GP, Hrushesky WJ: A murine renal cell carcinoma. J Natl Cancer Inst 1973, 50:1013-1025
19. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM: Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000, 156:1363-1380
20. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997, 57:1829-1834
21. Yu JL, Rak JW, Carmeliet P, Nagy A, Kerbel RS, Coomber BL: Heterogeneous vascular dependence of tumor cell populations. Am J Pathol 2001, 158:1325-1334
22. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM: Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002, 160:985-1000
23. Tian S, Hayes AJ, Metheny-Barlow LJ, Li LY: Stabilization of breast cancer xenograft tumour neovasculature by angiopoietin-1. Br J Cancer 2002, 86:645-651
24. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103:159-165
25. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG: Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies. Cancer Res 2000, 60:1388-1393
26. Reinmuth N, Liu W, Jung YD, Ahmad SA, Shaheen RM, Fan F, Bucana CD, McMahon G, Gallick GE, Ellis LM: Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. EMBO J 2001, 15:1239-1241
27. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS: Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002, 295:1526-1528
28. Lee JC, Kim DC, Gee MS, Saunders HM, Sehgal CM, Feldman MD, Ross SR, Lee WM: Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomas. Cancer Res 2002, 62:747-755
29. Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, Coomber BL, Rak J: Possible mechanisms of acquired resistance to antiangiogenic drugs: Implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001, 20:79-86
30. Luster AD, Greenberg SM, Leder P: The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 1995, 182:219-231